Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.39 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659319 | 0.91 | HPGDS (0.42) | NTRK1SCN5AHPGDSORAI1STIM1 | |
| SCHEMBL29405919 | 0.91 | HPGDS (0.42) | NTRK1SCN5AHPGDSORAI1STIM1 | |
| SCHEMBL29406420 | 0.89 | NTRK1 (0.47) | NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL24571213 | 0.89 | NTRK1 (0.47) | NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL22659855 | 0.88 | BRAF (0.42) | NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL22659819 | 0.87 | MCHR1 (0.41) | TRPV1NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL22659859 | 0.87 | NTRK1 (0.42) | NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL29405116 | 0.87 | NTRK1 (0.42) | NTRK1HPGDSORAI1STIM1 | |
| SCHEMBL22659086 | 0.87 | NTRK1 (0.50) | NTRK1HPGDS | |
| SCHEMBL24571216 | 0.86 | KCNT1 (0.46) | NTRK1SCN5AHPGDSORAI1STIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | SCN9A 4817/4885TRPV1 336/4885NTRK1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.